key: cord-0981591-fyif4nhm
authors: Berguer, Paula M.; Blaustein, Matías; Bredeston, Luis M.; Craig, Patricio O.; D’Alessio, Cecilia; Elias, Fernanda; Farré, Paola C.; Fernández, Natalia B.; Gentili, Hernán G.; Gándola, Yamila B.; Gasulla, Javier; Gudesblat, Gustavo E.; Herrera, María G.; Ibañez, Lorena I.; Idrovo-Hidalgo, Tommy; Nadra, Alejandro D.; Noseda, Diego G.; Paván, Carlos H.; Pavan, María F.; Pignataro, María F.; Roman, Ernesto A.; Ruberto, Lucas A. M.; Rubinstein, Natalia; Sanchez, María V.; Santos, Javier; Wetzler, Diana E.; Zelada, Alicia M.
title: Production of a Highly Immunogenic Antigen from SARS-CoV-2 by Covalent Coupling of the Receptor Binding Domain of Spike Protein to a Multimeric Carrier
date: 2021-04-26
journal: bioRxiv
DOI: 10.1101/2021.04.25.441271
sha: 5df77f314588f3a4c79d476e19b141fcfc282a26
doc_id: 981591
cord_uid: fyif4nhm

Since the discovery of SARS-CoV-2, several antigens have been proposed to be part of COVID-19 vaccines. The receptor binding domain (RBD) of Spike protein is one of the promising candidates to develop effective vaccines since it can induce potent neutralizing antibodies. We previously reported the production of RBD in Pichia pastoris and showed it is structurally identical to the protein produced in mammalian HEK-293T cells. In this work we designed an RBD multimer construct with the purpose of increasing RBD immunogenicity. We produced multimeric particles by a transpeptidation reaction between the RBD expressed in P. pastoris and Lumazine Synthase from Brucella abortus (BLS), which is a highly immunogenic and very stable decameric protein of 170 kDa. We vaccinated mice with two doses 30 days apart, and then we measured humoral immune response. When the number of RBD copies coupled to BLS was high (6-7 RBD molecules per BLS decamer, in average), the immune response was significantly better than that elicited by RBD alone or even by RBD-BLS comprising low number of RBD copies (1-2 RBD molecules per BLS decamer). Remarkably, the construct with high number of RBD copies induced high IgG titers with high neutralizing capacity. Furthermore, a superior immune response was observed when Al(OH)3 adjuvant was added to this formulation, exhibiting a higher titer of neutralizing antibodies. Altogether our results suggest that RBD covalent coupled to BLS forming a multimer-particle shows an advantageous architecture to the antigen-presentation to the immune system which enhances immune responses. This new antigen should be considered a potent candidate for a protein-based vaccine.

The coronavirus SARS-CoV-2, which was detected about one year ago in Wuhan, Republic of China in December 2019, has produced over 3.0 million deaths by April, 2021 (https://ourworldindata.org/covid-deaths). Since the discovery of the new strain, several vaccines have been developed (https://covid19.trackvaccines.org/vaccines/), based on inactivated viruses, DNA, RNA and/or proteins [1] [2] [3] . Furthermore, multivalent antigens that mimic antigen presentation by viral particles have been shown to induce a stronger immune response than monomeric antigens 4 , thus allowing immunization with lower doses of antigen, as well as the combination of different antigen variants. This approach would be critical in the specific case of new circulating SARS-CoV-2 lineages that have unfortunately emerged around the world 5 .

The receptor binding domain (RBD) of SARS-CoV-2 Spike protein is responsible for the interaction of the virus with the receptor Angiotensin-Converting Enzyme 2 (ACE2) 6 , which allows the penetration of the virus into the cells. Therefore, RBD constitutes a suitable target to develop diagnostic and therapeutic tools, as well as vaccines. It has been found that several neutralizing antibodies produced upon SARS-CoV-2 infection are directed towards RBD 7, 8 . The structure of the complex formed by SARS-CoV-2 RBD and human ACE2 was recently determined 9 . Unlike SARS-CoV-1, several residue changes in SARS-CoV-2 RBD stabilize two virus-binding hotspots at the RBD/ACE2 interface increasing the affinity for ACE2 9 .

SARS-CoV-2 Spike's RBD is a challenging protein to produce in heterologous systems because it has nine cysteine residues (eight of which form disulfide bonds), a complex topology and two N-glycosylation sites 10, 11 . For these reasons, RBD is often expressed in mammalian cells 9, 12 . Nevertheless, our AntiCovid consortium was able to produce RBD at high yields in Pichia pastoris. Its immunogenicity, stability and biophysical properties were similar to those of RBD produced in mammalian HEK-2913T cells; notably, combined with adjuvants it elicited humoral immune response in mice 12 . Remarkably, the production of RBD in yeast cells is more cost effective compared to other systems, and the fermentation bioprocess can be scaled up under Good Manufacturing Practice conditions. We were capable of optimizing RBD expression in P. pastoris to reach yields of 180 mg/L of ～90% pure protein, and thus were able to supply it to the Argentinian scientific community and health system at a low cost. It is currently used as an antigen for serological test kits, and as an immunogen. RBD could be used to produce neutralizing antibodies at large scale in animal systems such as egg yolk (IgY) 13, 14 or in horses 15 .

While RBD is immunogenic per se, the development of a highly immunogenic antigen is essential for the development of new generation subunit vaccines, which ideally should be capable of simultaneously providing immunity against the different emerging RBD variants. A possible strategy to achieve this goal is to couple the protein of interest to an immunogenic carrier protein. Lumazine synthase (LS, EC 2.5.1.78) from Brucella abortus (BLS) is a highly immunogenic and very stable decameric protein ideally suited to function as an immunogenic carrier protein. Five BLS subunits (17 kDa each) form a pentamer, and two pentamers form a very stable decamer. Such decamers may be decorated with any protein whose antigenicity needs to be increased. The BLS decamer has been used to significantly increase the immunogenicity of other proteins by means of the fusion between the C-terminus of the foreign protein and the N-terminus of BLS, showing that BLS is a convenient platform for antigen display [16] [17] [18] .

Moreover, BLS activates dendritic cells in vitro, increasing the levels of co-stimulatory molecules and the secretion of proinflammatory cytokines, and also recruits dendritic cells in vivo, in both cases in a TLR4-dependent manner 19 . In addition, BLS chimeras are extremely effective to rapidly activate specific CD8+ lymphocytes, and to induce significant cytotoxic activity 20 . While other carrier proteins have been non-covalently attached to target proteins through a pair of interacting proteins (e.g. X-dockerin-cohesin-Y 21 where X and Y are proteins expressed as a fusion protein with the dockerin and cohesin domains, respectively), such non-covalent interactions might be relatively weak particularly for immunization purposes, which normally require the use of strong adjuvants. The translational fusion of target proteins and peptides with BLS has allowed researchers to overcome this problem 22 . However, given that BLS fusions are usually expressed at high yields in Escherichia coli, this strategy may be not adequate for proteins with a complex structure and high disulfide bonds content, and/or that require post translational modifications, as it is the case of RBD, which cannot be properly expressed in E. coli 12 . This problem could be circumvented through the covalent coupling of RBD and BLS, in vitro, in their native state, which can be achieved with the Sortase A enzyme.

Sortase A and its variants can efficiently catalyze a transpeptidation reaction that creates a covalent link between two native proteins or peptides 23 . This reaction requires that the N-terminal protein to be covalently linked contains a specific signal located in its C-terminal stretch: Protein N -Leu-Pro-X-Thr-Gly (Figure 1 ). This site should preferably be in an unstructured context, and the Gly residue is usually followed by a histidine tag to facilitate its purification process. The C-terminal protein to be covalently linked should contain three Gly amino acid residues in its N-terminal region (Gly-Gly-Gly-Protein C ). After the Sortase A transpeptidation reaction, both subunits are joined to produce the covalently-linked product Protein N -Leu-Pro-X-Thr-Gly-Gly-Gly-Protein C (Figure 1) . Therefore, the Sortase A-mediated transpeptidation reaction can couple preassembled oligomeric carriers such as BLS, or virus-like particles (VLPs), to an immunogen expressed in a different system 24 . An additional advantage of Sortase A-mediated coupling is that the scar of the transpeptidation reaction in the protein product is of only seven residues, of which three are glycines. The enzymatic intermediary form (RBD covalent bound to Sortase A) is shown, and the hydrolysis of the intermediary to yield the by-product RBD-Leu-Pro-Glu-Thr is included. The latter cannot be reused in the coupling reaction. The reaction catalyzed by TEV protease to yield Gly-Gly-Gly-BLS, the substrate of Sortase A is also shown. (B) A hypothetical reaction product with a multiplicity of 10:10 (RBD 10 /BLS 10 ) is shown.

In this work, we produced a multimeric RBD-BLS by a Sortase A-mediated transpeptidation covalent coupling reaction between RBD expressed in P. pastoris and BLS produced in E. coli, with the purpose of increasing RBD immunogenicity. RBD-BLS induced a strong humoral response against SARS-CoV-2 RBD. Remarkably, the RBD antigen produced a significantly higher humoral response when presented to the immune system in the context of an RBD-BLS multimer with a high number of RBD molecules per particle (high multiplicity) than as a monomer, or within low multiplicity particles. The RBD-BLS multimer is a potential vaccine candidate, and can also be useful to produce neutralizing antibodies in animal systems. This platform could be also used to simultaneously present several proteins to the immune system, such as different RBD variants and other domains of the spike protein.

In order to obtain a multimeric carrier for RBD, we first produced an oligomeric form of BLS in E. coli. For this purpose we synthesized and sequenced a gene encoding a BLS carrier protein variant which included in its N-terminal region a TEV protease cleavage site (in italics) followed by a Gly-tag (Met-Glu-Asn-Leu-Tyr-Phe-Gln-Gly-Gly-Gly-BLS) (Figure 1 ). This strategy allows the removal of the N-terminal Met after a quantitative digestion with the TEV protease, thus producing a polypeptide carrying an N-terminal Gly-Gly-Gly required for the Sortase A-mediated transpeptidation reaction. Following BLS expression in E. coli, the protein was purified in two steps, by anion exchange chromatography (Q-Sepharose) followed by size exclusion chromatography (SEC-HPLC, Superdex S200). The protein was obtained with a high yield (100 mg L -1 , >98% purity), and its identity was verified after purification by mass spectrometry. BLS was then digested with TEV protease to generate the N-terminal Gly-Gly-Gly motif so that it can function as a Sortase A substrate. The digestion was confirmed by SDS-PAGE and mass spectrometry (Figures S1 and S2) , which showed the expected "activated" multimeric carrier Gly-Gly-Gly-BLS. It is worth mentioning a complete TEV digestion of BLS was observed.

To generate the second substrate of the coupling reaction, an RBD variant including a Sortase A recognition signal (Leu-Pro-Glu-Thr-Gly-) followed by a (His) 6 -tag at its C-terminus was produced in P. pastoris (RBD-Leu-Pro-Glu-Thr-Gly-(His) 6 ) and obtained from culture supernatants with a high yield (180 mg L -1 , >90% purity). We have previously shown that this protein is conformationally stable and drives a significant immune response in mice when administered in a formulation with adjuvants 25 . We assessed the tertiary structure of the purified RBD through near-UV-CD spectroscopy. The results are compatible with an asymmetric and rigid environment of the aromatic side chains, indicating a native packing (Figures 2A and B) .

Moreover, the protein does not exhibit significant aggregation, as inferred from the SEC-HPLC profiles and the absence of species with low elution volumes ( Figure 2C ). In addition, as previously observed 25 

To evaluate the ability of recombinant RBD-Leu-Pro-Glu-Thr-Gly-(His) 6 to act as a Sortase A substrate, we first carried out a preliminary reaction using the fluorescent peptide probe Gly-Gly-Gly-Ser-{Lys-(TMR)} as a substrate instead of BLS. This peptide contains a covalently bound tetramethylrhodamine (TMR) label. The product of this reaction was the covalently coupled RBD-Leu-Pro-Glu-Thr-Gly-Gly-Gly-Gly-Ser-(Lys-TMR) (RBD-TMR).

After the coupling reaction and SEC (G25) separation, nearly 17% of input RBD was labeled with the fluorescent probe as inferred from UV and visible spectra analysis (Figures 3A and B) .

The unreacted RBD retained the (His) 6 tag, and could therefore be separated and recovered by addition of NTA resin to the reaction mix followed by centrifugation. This procedure produced a final yield of~50% labelled RBD. Moreover, SEC-HPLC analysis, monitored at 554 nm, which allows detection of the TMR label, revealed the presence of the reaction product. However, no free fluorescent peptide was observed in the elution profile ( Figure 3C) , indicating that the G25 matrix was capable of separating the residual free peptide. SEC-HPLC (using the Superose 6 column) of the reaction product showed an absence of peaks at short elution times, suggesting that RBD-TMR was not prone to aggregation after the covalent coupling of the probe. These results showed that Sortase A was functional, and it was possible to carry out the covalent coupling between recombinant RBD and a Gly-Gly-Gly-tagged substrate.

UV and (B) visible spectra of the free fluorescent probe (blue) and the coupling reaction product RBD-TMR (green) after a G25 column separation. The RBD spectrum is also shown as a reference (red) (C) SEC-HPLC elution profiles (Superose 6 column) of RBD (monitored at 280 nm, red), TMR (monitored at 554 nm, blue) and RBD-TMR (monitored at 554 nm, green) after coupling and G25 separation.

In addition to the conformational analysis, we also assessed the functionality of purified RBD-TMR. Therefore, we tested its ability to bind RBD natural receptor during viral infection, the human ACE2. For this purpose, we incubated (a) the labeled protein (RBD-TMR), (b) a soluble version of ACE2 with a C-terminal (His) 6 tag, and (c) agarose-NTA-Ni 2+ resin ( Figure   4A ) during 30 min. Next, we separated the ternary complex ACE2/RBD-TMR/agarose-NTA-Ni 2+ by centrifugation. The matrix agarose-NTA-Ni 2+ interacts with the (His) 6 tag that it is present only in the C-terminal of ACE2 (and not in RBD-TMR), thus pulling down bound RBD-TMR and consequently producing a significant decrease of the supernatant fluorescence intensity (570-580 nm, Figure 4B ). Elution of the complex from the NTA matrix by addition of 300 mM imidazole caused a strong fluorescence increase in the soluble fraction, further indicating that (His) 6 -tagged ACE2 forms a complex with RBD-TMR ( Figure 4C ). We concluded that RBD-TMR was capable of interacting with the ACE2 soluble domain, indicating that the structural features relevant for the interaction are preserved in recombinant RBD produced in P. pastoris, and that the conditions employed to perform the transpeptidation reaction to produce RBD-TMR did not affect its tertiary structure. Tris-HCl pH 8.0, 150 mM NaCl and 250 mM imidazole. The sample was centrifuged, and the supernatant was analyzed by fluorescence spectroscopy (C). In B and C black lines correspond to the incubation in the presence of ACE2, while red lines correspond to the controls without ACE2. The excitation wavelength was 550 nm, the bandwidths for both excitation and emission were of 5 nm. All the measurements were made at 25 °C.

Given that recombinant RBD proved to be a good Sortase A substrate, we proceeded to attempt the coupling of RBD-Leu-Pro-Glu-Thr-Gly-(His) 6 and TEV-digested

Met-Glu-Asn-Leu-Tyr-Phe-Gln-Gly-Gly-Gly-BLS. The expected product was the covalently coupled RBD-Leu-Pro-Glu-Thr-Gly-Gly-Gly-Gly-Ser-Gly-Ser-Gly-BLS (RBD-BLS in Figure   1 ). The SEC-HPLC profiles (Superose 6 column) corresponding to a BLS multimer, RBD alone and the reaction product are shown in Figure 5A . The product of the covalent coupling mediated by Sortase A exhibited an elution time compatible with an increment in the hydrodynamic radius of the assembly compared to that observed for the decameric BLS (27 and 31.5 min, respectively). The unreacted BLS decamer and RBD are also clearly distinguishable in the SEC profile.

Since BLS is a decameric protein, different multiplicities (RBD n /BLS 10 ) can be obtained depending on the buffer conditions and the stoichiometry of the Sortase A reaction. It was possible to obtain different multiplicities by controlling RBD and BLS concentration ratios. We used low RBD and high BLS concentration, to obtain low multiplicities (between 1 and 2 of RBD copies per multimer, Figure S3 ), referred as RBD-BLS LM), whereas the higher multiplicities (referred as RBD-BLS HM) were obtained with higher RBD/BLS ratios ( Figure   S3 and Figure 5A ).

To determine such multiplicities, and given that the presence of heterogeneous sizes of glycan moieties in RBD resulted in a high heterogeneity which difficults the analysis, we trimmed the kDa) was observed that still needs to be identified (lanes 3 and 4).

A quantification of the loss of free BLS and the increment of the RBD-BLS band in SDS-PAGE (and HPLC) allowed us to quantify the yield and the multiplicity (Figure S4) , that is the number of RBD copies per RBD-BLS particle, of the coupling reaction. We have obtained preliminary yields of 10-30% with average multiplicities between 2 and 4 (RBD 2 /BLS 10 and RBD 4 /BLS 10 , respectively) in preliminary experiments. However, the incorporation of a concentration step (the reaction made in a centrifugal filter unit (Centricon, Merck Millipore) with a cutoff of 10 kDa, see Materials and Methods for details) allowed us to enhance the reaction, yielding in higher multiplicities (between RBD 6. /BLS 10 and RBD 7. /BLS 10 , RBD-BLS HM).

In summary, we succeeded in coupling the eukaryotic-produced RBD antigen with the E.coli expressed decameric carrier BLS under native conditions. In addition, the possibility of obtaining RBD-BLS with different multiplicities allowed to study the effect of multiplicity on the development of the immune response. An equivalent volume of a 10 mM EDTA, 10 mM CaCl 2 solution was loaded as a control (magenta, lower pane). Decameric BLS has a molecular weight of approximately 170 kDa and each RBD subunit adds approximately 26 kDa or 40 kDa (excluding or including glycosylation, respectively). The observed multiplicity was~6.6 (RBD 6.6 /BLS 10 ) with a yield of~20%. The RBD-BLS oligomer eluted at~25 min. The peak observed between 38-43 min corresponds to EDTA-Ca 2+ . Sortase A requires 10 mM CaCl 2 for the activation of its catalytic activity, therefore 10 mM EDTA was added to stop the reaction, which was carried out during 240 min at 4°C. Once purified by SEC, the coupling product was found to be stable after freezing and subsequent thawing, and did not show any significant aggregation tendency. In addition, the product could be easily concentrated, and did not show any apparent interaction with the concentrator membranes (data not shown). Importantly, the coupling products were also separated from the Sortase A enzyme by SEC. This is an essential step to avoid reverse transpeptidation and RBD-Sortase A hydrolysis (that would result in a RBDh product that can not be recycled by the enzyme) 26 , which would reduce the global yield of the reaction.

To assess whether RBD coupled to BLS can improve the immunogenicity of RBD, we immunized mice with two doses of RBD-BLS HM, RBD-BLS LM and monomeric RBD, 30 days apart ( Table 1 , Materials and Methods). In addition, RBD and RBD-BLS-HM formulations were adjuvanted with Al(OH) 3 .

The multimeric RBD-BLS HM formulation alone elicited a strong humoral response with high anti-RBD IgG titers, and when adjuvanted with AL(OH) 3 the humoral response increased 6.75 times relative to RBD-BLS HM alone (Figure 6 ). By contrast, monomeric RBD did not elicit a significant anti-RBD IgG specific antibody response even in presence of Al(OH) 3 . We also observed that the addition of BLS to monomeric RBD (at the same BLS concentration used in the case of RBD-BLS HM) slightly improved humoral immune response (RBD + BLS group).This result suggests that BLS showed some adjuvant ability per se. Furthermore, the multiplicity of RBD-BLS multimers turned out to be a key variable, since a high multiplicity elicited strong immune response, while a low multiplicity did not (RBD-BLS LM group, between 1 and 2 copies of RBD per multimer).

These results clearly show that coupling of RBD to BLS at high multiplicity strongly enhances RBD immunogenicity, which might be due at least in part to the spatial arrangement of the RBD subunits in the resulting particles ( Figure 1B) . 

To analyze the neutralizing activity of immune sera elicited by RBD-BLS immunization, in vitro neutralization assays using SARS-CoV-2 S pseudotyped lentiviruses were performed 27 . Table 1 , RBD + BLS).

Altogether these results show that RBD-BLS HM is a very promising candidate both to induce neutralizing antibodies in animal models, and as a candidate for a protein-based vaccine. 

A year ago, just before SARS-CoV-2 was first detected in Argentina, a group of researchers from different institutions and with different relevant expertises joined forces to help fighting the ongoing pandemic. Our work aimed to produce the RBD domain of SARS-CoV-2 spike protein, as it is a useful tool for the serological detection of infected patients, and has the potential to be used as antigen to develop a low cost vaccine. So far we have successfully produced RBD in different expression systems, among them in the yeast P. pastoris, which showed biophysical properties similar to that of RBD expressed in mammalian cells 25 .

In this work RBD was covalently coupled to a multimeric carrier with the aim of improving its immunogenicity to develop a useful vaccine candidate. As a carrier we used the multimeric lumazine synthase protein from Brucella abortus (BLS), which has been previously shown to be a good antigen carrier for systemic immunization and as mucosal-adjuvant, which makes it a good candidate to be used for oral subunit vaccines 17 . We have improved the efficiency of the RBD-BLS coupling reaction to scale up the production and purification of the RBD-BLS oligomer, obtaining different multiplicities (1 to 6) and we have compared the immunogenicity of RBD-BLS vs. RBD in mice.

Our results showed that the RBD-BLS multimer can elicit an increased immune response compared to that of monomeric RBD, even in the absence of adjuvant. This increase depended on the covalent coupling of RBD to BLS, as the co-administration of RBD with BLS (i.e. not covalently coupled) did not induce an equivalent immune response. We also observed that the multiplicity of RBD coupled to BLS was an important factor in the enhancement of the immunological response.

In immunological studies we observed that RBD coupled to BLS at a high multiplicity (6-7 RBD copies per BLS decamer) is remarkably more immunogenic than monomeric RBD, or than RBD coupled to BLS at a low multiplicity (1-2 RBD copies per BLS decamer). An 80-fold increment in the anti-RBD humoral immune response was observed by RBD-BLS HM compared to monomeric RBD. By contrast, no significant humoral immune response was elicited by monomeric RBD in the presence or absence of Al(OH) 3 , or by the addition of BLS to RBD (without covalent coupling). In addition, when Al(OH) 3 was added to RBD-BLS HM an extra 6.75-fold increase in total anti-RBD IgG titer and 4.1 fold increase in sera neutralization IC 50 value was observed.

Whereas BLS is highly resistant to urea-induced unfolding, the decameric structure is sensitive to low pH (pH 4.0-5.5), or to moderate guanidinium chloride concentrations (2.0 M) 28 , which cause the dissociation of the decameric forms to pentamers. In addition, BLS has been previously modified, and several pentameric variants also exist that could be used to assemble pentamers, which could then be mixed to obtain the decameric form, taking advantage of surface complementation that depends on the new side-chain residues on these surfaces 29 . This makes BLS a very malleable protein, and would allow, for example, to include different immunogens in the same protein particle. BLS oligomers carrying different coupled proteins could be disassembled by incubation at low pH, mixed and reassembled so as to generate a diversity of homo and hetero decamers. As a Toll-like receptor (TLR) agonist, it has been shown that BLS can stimulate both innate and adaptive immune responses, thereby improving vaccine efficacy 17, 20 . Thus RBD-BLS, alone or in combination with adjuvants, has the potential to boost T-and B-cell responses against SARS-CoV-2, which deserves further exploration.

The idea of coupling RBD to a multimeric protein to produce a stronger immunogen has been considered by other groups. Some molecular platforms have been proposed to multimerize CoV antigens. A very interesting recent work reports the production of particles displaying regions of the Middle East respiratory syndrome coronavirus (MERS-CoV) spike protein, by coupling its RBD domain to a multimeric lumazine synthase (LS), using the SpyTag/SpyCatcher system 30 pylori ferritin, a 19 kDa protein that self-assembles into a 24-subunit nanoparticle 33 . Of note, such nanoparticles display eight copies of a trimeric antigen on the surface, as previously used for haemagglutinin from H1N1 virus 34 . The authors showed that multivalent presentation of spike trimers on ferritin can notably increase elicitation of neutralizing antibodies in mice after a single dose.

In this context, the strategy presented here involving RBD-BLS particles may be considered as a new useful tool against SARS-CoV-2. The platform is ductile enough to incorporate new variants like E484K, which has been associated with escape from neutralizing antibodies [35] [36] [37] or N501Y, which is associated with increased binding specificity and faster-growing lineages 38 .

This is important given the high chance of having new waves of SARS-CoV-2 involving RBD mutant viruses.

The receptor binding domain of spike protein from SARS-CoV-2 (RBD) was expressed in Pichia pastoris. The RBD coding sequence (spike amino acid residues 319-537) was fused to the Saccharomyces cerevisiae alpha factor secretion signal (N-terminal) followed by a C-terminal Sortase A recognition sequence and a His 6 tag (C-terminal) given the C-terminal sequence RBD-Leu-Pro-Glu-Thr-Gly-(His) 6 as previously reported 25 . The expression was carried out in a bioreactor as indicated, and the protein was purified with a yield of 150 mg L -1 of culture supernatant 25 . RBD concentration was determined by UV spectrophotometry using an absorption coefficient of 33850 M -1 cm -1 .

A gene encoding a variant of lumazine synthase of Brucella abortus (BLS) including an N-terminal TEV site followed by a Gly-Gly-Gly sequence and a Gly-Ser-GLy-Ser-GLy spacer 

The expression plasmid pcDNA3-sACE2(WT)-8his, which includes the human ACE2 soluble domain (residues 1-615) coding gene, followed by a Gly-Ser-Gly linker and eight His residues for purification, was transfected in HEK-293T mammalian cells. Cells were grown in high glucose 

Tobacco Etch Virus protease (TEV) was a gift from Helena Berglund (Addgene plasmid # 125194 ; http://n2t.net/addgene:125194 ; RRID:Addgene_125194) 40 . Briefly, E coli Rosetta previously equilibrated with the lysis buffer. A washing step with 10 column volumes was performed, and the protein was eluted with 2.5 volumes of elution buffer (50 mM phosphate pH 8.0, 150 mM NaCl, 250 mM Imidazole, 10% glycerol). Finally, to remove imidazole, the protein was subjected to dialysis and stored at -80 ºC in small fractions.

The 

The protein samples were analyzed on an LC−ESI-MS platform consisting of a Surveyor MS 

CD spectra measurements were carried out at 20°C with a Jasco J-815 spectropolarimeter.

Near-UV CD spectra were collected using cells with path lengths 1.0 cm. High tension voltage was registered simultaneously. Data was acquired at a scan speed of 20 nm min -1 (five scans were averaged, scans corresponding to buffer solution were averaged and subtracted from the spectra). Values of ellipticity were converted to molar ellipticity.

The tetramethylrhodamine (TMR) labeled peptide with sequence

Gly-Gly-GLy-Ser-{Lys-(TMR)}was purchased from Genscript. Its mass, as determined by mass spectrometry analysis, and excitation and emission spectra were compatible with the predicted theoretical values. An absorption coefficient of 87500 M -1 cm -1 at 560 nm was used to calculate the TMR concentration in solution. To evaluate the transpeptidation efficiency, a spectrum of free TMR was subtracted from the spectrum of protein in order to correct the 280 nm absorbance value of the protein solution.

The transpeptidation reaction was performed by the Sortase A enzyme. To obtain a product with high multiplicity ( 

Size exclusion chromatography (SEC-HPLC) was carried out using a Superose-6 column (GE Healthcare). The protein concentration was 10-30 μM, a volume of 50 μL was typically injected, and the running buffer was 20 mM Tris-HCl, 100 mM NaCl, 1 mM EDTA, pH 7.0. The experiment was carried out at room temperature (∼25 ºC) at a 0.5 mL min -1 flow rate. A JASCO HPLC instrument was used. It was equipped with an automatic injector, a quaternary pump and a UV-VIS UV-2075 (the elution was monitored at 280 nm).

The interaction between the covalently coupled product RBD-TMR and the ACE2 soluble domain was studied taking advantage of the presence of a (His) 6 

Lipopolysaccharide (LPS) 42 was removed from the protein preparations by an overnight incubation (4 ºC) of the proteins with polymyxin B matrix followed by a second incubation (2) (3) h) at room temperature. The matrix was previously equilibrated in 20 mM Tris-HCl, 100 mM NaCl, pH 7.0 buffer solution. We measured the LPS content of purified RBD-BLS preparations as previously described 19 Table 1 ) was tested with the same equimolar conditions used for the RBD-BLS HM group.

The antibody response against RBD and RBD-BLS was measured using a standard ELISA The antibody titer was determined as the inverse of the last dilution that was considered positive, with a cut-off value defined as absorbance at 450 nm of 0.20, which was twice as high as that from a pool of normal mouse sera (from 30 unimmunized animals). Statistical significance was evaluated by the Student's t-test, using a logarithmic transformation of the ELISA titers. Differences were considered significant if p < 0.05. 

Addgene plasmid #11619) and David Liu for providing us with Sortase A pentamutant (Addgene plasmid #75144)

SARS-CoV-2 vaccines in development

A Review of the Progress and Challenges of Developing a Vaccine for COVID-19

Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate

Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice

Pervasive transmission of E484K and emergence of VUI-NP13L with evidence of SARS-CoV-2 co-infection events by two different lineages in Rio Grande do Sul, Brazil

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability

A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Structural basis of receptor recognition by SARS-CoV-2

Site-specific glycan analysis of the SARS-CoV-2 spike

Deducing the N-and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Chicken Egg Yolk Antibodies (IgYs) block the binding of multiple SARS-CoV-2 spike protein variants to human ACE2

Generation of Chicken IgY against SARS-COV-2 Spike Protein and Epitope Mapping

Development of a hyperimmune equine serum therapy for COVID-19 in Argentina

Characterization of structural and immunological properties of a fusion protein between flagellin from Salmonella and lumazine synthase from Brucella

Brucella spp. lumazine synthase: a novel adjuvant and antigen delivery system to effectively induce oral immunity

Expression of the multimeric and highly immunogenic Brucella spp. lumazine synthase fused to bovine rotavirus VP8d as a scaffold for antigen production in tobacco chloroplasts

A polymeric bacterial protein activates dendritic cells via TLR4

A polymeric protein induces specific cytotoxicity in a TLR4 dependent manner in the absence of adjuvants

Engineered proteins containing the cohesin and dockerin domains from Clostridium thermocellum provides a reversible, high affinity interaction for biotechnology applications

Multiple display of a protein domain on a bacterial polymeric scaffold

Sortase A: A model for transpeptidation and its biological applications

A modular vaccine development platform based on sortase-mediated site-specific tagging of antigens onto virus-like particles

Structural and functional comparison of SARS-CoV-2-spike receptor binding domain produced in Pichia pastoris and mammalian cells

Kinetic mechanism of Staphylococcus aureus sortase SrtA

Effective screening of SARS-CoV-2 neutralizing antibodies in patient serum using lentivirus particles pseudotyped with SARS-CoV-2 spike glycoprotein

High order quaternary arrangement confers increased structural stability to Brucella sp. lumazine synthase

Asymmetric bifunctional protein nanoparticles through redesign of self-assembly

Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV

Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin

A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone

A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice

Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies

The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera

SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition

Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy

Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2

Improved solubility of TEV protease by directed evolution

Site-Specific Protein Labeling via

Methods of endotoxin removal from biological preparations: a review

Generation of SARS-CoV-2 Spike pseudotyped virus for viral entry and neutralization assays: A 1-week protocol

Pseudotype neutralization assays: from laboratory bench to data analysis

We thank LANAIS-PRO-EM for the support with mass spectrometry analysis of proteins and peptides, and Fundación Ciencias Exactas y Naturales from Universidad de Buenos Aires for their help. Also we would like to thank Santigo Sosa for suggestions concerning BLS and Dr.Fernando Goldbaum for providing us a BLS variant without Cys residues. We thank Erik Procko for providing us with pcDNA3-sACE2(WT)-8his (Addgene plasmid #149268), Stephan Kissler 

UniProtKB -P0DTC2 (SPIKE_SARS2); Spike glycoprotein from SARS-CoV-2.UniProtKB -Q2YKV1 (RISB2_BRUA2); 6,7-dimethyl-8-ribityllumazine synthase 2.UniProtKB -Q9BYF1 (ACE2_HUMAN); human angiotensin-converting enzyme 2.

Pre-immune sera also were collected before starting the immunization. Mice received two immunizations with the same dose at days 0 (antigen prime) and 30 (antigen boost). Additional control animals were injected with 500 µg Al(OH) 3 per mouse with the same immunization schedule.Blood samples were obtained at 20 days post-second immunization by venipuncture from the facial vein. After coagulation at room temperature for 1-2 h, blood samples were spun in a centrifuge at 3000 rpm/min for 10 min at 4°C. The upper serum layer was collected and stored at -20°C. 

All authors from the Argentinian AntiCovid Consortium (*) designed experiments, performed research, analyzed data and drafted the manuscript. All authors (listed in alphabetical order) contributed equally to this work. P. C. F. determined endotoxin contents in the protein samples prior to the formulation for immunizations.

The author(s) declare no competing interests.